Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Verastem

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 73

Market Cap: -

Website: http://www.verastem.com

Introduction: Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Clinical Trials

A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Colorectal Cancer
Solid Tumor, Adult
G12D Mutated KRAS

Interventions: Drug: VS-7375
Drug: Cetuximab

First Posted Date: 2025-06-13

Last Posted Date: 2025-06-18

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 130

Registration Number: NCT07020221

Locations: 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Phase 2

Recruiting

Conditions: Low Grade Serous Ovarian Cancer
Ovarian Cancer

Interventions: Drug: Avutometinib (VS-6766) + Defactinib (VS-6063)

First Posted Date: 2024-11-12

Last Posted Date: 2025-02-17

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 15

Registration Number: NCT06682572

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan
🇯🇵
Mie University Hospital, Tsu, Mie, Japan

and more 2 locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Phase 3

Recruiting

Conditions: Low Grade Serous Ovarian Cancer

Interventions: Drug: avutometinib
Drug: Pegylated liposomal doxorubicin
Drug: Defactinib
Drug: Paclitaxel
Drug: Letrozole
Drug: Anastrozole

First Posted Date: 2023-10-10

Last Posted Date: 2025-07-02

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 270

Registration Number: NCT06072781

Locations: 🇺🇸
HonorHealth, Phoenix, Arizona, United States
🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸
UCLA Health, Los Angeles, California, United States

and more 94 locations

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Phase 1

Recruiting

Conditions: Metastatic Cancer
Pancreas Cancer
Neoplasms Pancreatic
Malignant Neoplasm of Pancreas
KRAS Activating Mutation

Interventions: Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel

First Posted Date: 2022-12-30

Last Posted Date: 2025-06-24

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 40

Registration Number: NCT05669482

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
KRAS Activating Mutation
Advanced Cancer
Metastatic Cancer
Malignant Neoplastic Disease
Malignant Neoplasm of Lung

Interventions: Drug: avutometinib (VS-6766) and adagrasib

First Posted Date: 2022-05-17

Last Posted Date: 2025-05-18

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 85

Registration Number: NCT05375994

Locations: 🇺🇸
UCSF Thoracic Oncology, San Francisco, California, United States
🇺🇸
University of Colorado Hospital Anschutz Cancer Pavllion, Aurora, Colorado, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 4 locations

Food Effect of VS-6766 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Food Effect

Interventions: Drug: VS-6766

First Posted Date: 2022-01-11

Last Posted Date: 2022-05-10

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 18

Registration Number: NCT05187169

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Phase 1

Recruiting

Conditions: KRAS Activating Mutation
Non Small Cell Lung Cancer

Interventions: Drug: avutometinib and sotorasib and defactinib
Drug: avutometinib and sotorasib

First Posted Date: 2021-10-12

Last Posted Date: 2025-02-04

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 153

Registration Number: NCT05074810

Locations: 🇺🇸
Rocky Mountain Cancer Center, LLP, Boulder, Colorado, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,, Washington, District of Columbia, United States

and more 29 locations

A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Phase 2

Active, not recruiting

Conditions: Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer

Interventions: Drug: avutometinib (VS-6766)
Drug: avutometinib (VS-6766) and defactinib

First Posted Date: 2020-11-12

Last Posted Date: 2025-01-29

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 225

Registration Number: NCT04625270

Locations: 🇺🇸
Arizona Oncology Associates PC HAL, Scottsdale, Arizona, United States
🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

and more 41 locations

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: KRAS Activating Mutation
Non Small Cell Lung Cancer

Interventions: Drug: avutometinib (VS-6766)
Drug: avutometinib (VS-6766) and Defactinib

First Posted Date: 2020-11-06

Last Posted Date: 2024-01-12

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 90

Registration Number: NCT04620330

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States

and more 40 locations

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Phase 1

Terminated

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Part A - VS-6063
Drug: Part A - Avelumab

First Posted Date: 2016-10-24

Last Posted Date: 2019-04-30

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 98

Registration Number: NCT02943317

Locations: 🇺🇸
Florida Cancer Specialists & Research Institute (FCS), Sarasota, Florida, United States
🇺🇸
Dana Farber Cancer Instiyute, Boston, Massachusetts, United States
🇺🇸
Stephenson Cancer Center (University of Oklahoma), Oklahoma City, Oklahoma, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy